Evidence mapPaperPMID 38529655Full record

Trial reportJournal of the American Heart Association2024

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.

Konstantinos I Gkarmiris, Johan Lindbäck, John H Alexander, Christopher B Granger, Peter Kastner, Renato D Lopes, André Ziegler, Jonas Oldgren, Agneta Siegbahn, Lars Wallentin and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: exploratory analysis of the EAST-AFNET 4 biomolecule study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  2. Prevalence and severity of atrial cardiomyopathy in patients with recently diagnosed atrial fibrillation and stroke risk factors and its association with early rhythm control: a secondary analysis of EAST-AFNET 4.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  3. Trial
  4. Comprehensive assessment of novel cardiovascular biomarkers in AF.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  5. Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  6. A novel technique for vein of Marshall blood sampling and its application in assessing atrial remodeling in atrial fibrillation.Clinical research in cardiology : official journal of the German Cardiac Society · 2025
    Article
  7. Article
  8. Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Konstantinos I GkarmirisDepartment of Medical Sciences Cardiology, Uppsala University Uppsala Sweden.ORCID 0009-0008-1453-0797
Johan LindbäckUppsala Clinical Research Center, Uppsala University Uppsala Sweden.ORCID 0000-0002-6473-8798
John H AlexanderDuke Clinical Research Institute, Duke University School of Medicine Durham NC USA.ORCID 0000-0002-1444-2462
Christopher B GrangerDuke Clinical Research Institute, Duke University School of Medicine Durham NC USA.ORCID 0000-0002-0045-3291
Peter KastnerRoche Diagnostics GmbH Penzberg Germany.
Renato D LopesDuke Clinical Research Institute, Duke University School of Medicine Durham NC USA.ORCID 0000-0003-2999-4961
André ZieglerRoche Diagnostics GmbH Penzberg Germany.
Jonas OldgrenDepartment of Medical Sciences Cardiology, Uppsala University Uppsala Sweden.ORCID 0000-0002-9969-3921
Agneta SiegbahnUppsala Clinical Research Center, Uppsala University Uppsala Sweden.ORCID 0000-0003-3955-5671
Lars WallentinDepartment of Medical Sciences Cardiology, Uppsala University Uppsala Sweden.ORCID 0000-0003-0378-6531
Ziad HijaziDepartment of Medical Sciences Cardiology, Uppsala University Uppsala Sweden.ORCID 0000-0002-7420-743X
Uppsala University · SEDuke University · USRoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. METHODS AND

resultsBMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878). Adjusted Cox-regression models were used to evaluate the association between 2-month BMP10 levels and outcomes. BMP10 levels increased by 7.8% (

conclusionsElevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF.

Indexed as

Atrial FibrillationBone Morphogenetic ProteinsHeart FailureStrokeAnticoagulantsBiomarkersEmbolismHumansIschemic StrokeRisk AssessmentWarfarinAnticoagulantsBiomarkersBMP10 protein, humanBone Morphogenetic ProteinsWarfarinatrial fibrillationbiomarkerBMP10risk stratificationstroke

Identifiers

PMID38529655
PMCPMC11179770
OpenAlexW4393354669

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.